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Abstract
Ductal carcinoma in situ (DCIS) represents a challenge for the breast unit team, begin-
ning from its difficult radiological detection and continuing with its controversial 
multimodal treatment and management. With the introduction of the mammographic 
screening, DCIS has become a common diagnosis. In fact, today DCIS is mostly identi-
fied by mammography or magnetic resonance imaging (MRI). The increased prevalence 
of DCIS diagnosis, in the past, raised the problem of the therapeutic management. In 
this chapter, the breast and axillary surgery in case of DCIS and the most controversial 
aspects regarding DCIS management are reviewed based on international guidelines and 
on the current literature.
Keywords: ductal carcinoma in situ, ductal intraepithelial neoplasia, breast-conserving 
surgery, sentinel lymph node biopsy, breast cancer, breast surgery
1. Introduction
Ductal carcinoma in situ (DCIS) represents a current challenge for the breast specialists, 
beginning from its difficult radiological detection and continuing with its controversial surgi-
cal and nonsurgical management. In this chapter, breast surgery and axillary surgery in case 
of DCIS are reviewed, as well as some aspects of its preoperative evaluation, based on the 
more recent international guidelines, and the controversial issues are discussed.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Histopathological aspects
The breast gland contains a ductal system that, with successive branches, ends distally in the 
terminal ductal-lobular units. Ducts and lobules are coated with two types of cells: luminal 
epithelial cells and myoepithelial cells. The myoepithelial cells contain myofilaments, have con-
tractile capacity, and form a network structure located on the basal membrane. Histologically, 
the retention of the myoepithelial cell layer helps to distinguish in situ forms from invasive ones.
DCIS is a neoplastic breast lesion, characterized by the presence in the ductal-lobular terminal 
unit of a malignant epithelial cell clone that does not exceed the basal membrane. DCIS includes 
a spectrum of different lesions from the histological point of view, with different architecture, 
nuclear morphology, degree, and the eventual presence of necrosis and calcifications.
DCIS has been historically divided into five histological subtypes, based on the tumor cell 
growth modality: comedogenic, solid, cribriform, papillary, and micropapillary; however, in 
most cases the appearance is composite.
Comedogenic DCIS is characterized by a solid proliferation of large pleomorphic cells, with 
abundant eosinophilic cytoplasm and high-grade hyperchromatic nuclei. A peculiar aspect of 
this DCIS is the presence of central necrosis which may give place to dystrophic calcifications, 
which are usually detected by mammography as clustered microcalcifications. Frequently, these 
lesions contain periductal fibrosis, due to the fibroblast response in the surrounding stroma, and 
a chronic inflammation component which may sometimes make these lesions clinically palpable.
Noncomedogenic DCIS consists of a population of smaller and monomorphic neoplastic cells, 
with variable nuclear grading. Necrosis is minimal or absent and the periductal fibrosis is 
unfrequent. In the cribriform subtype, neoformed glandular spaces are uniformly distributed 
and have a regular shape. In the solid DCIS, neoplastic cells completely fill in the interested 
tissue. The papillary subtype grows, giving rise to papillary formations with the fibrovas-
cular axis missing in the micropapillary DCIS, also characterized by interstitial papillary 
protrusions.
The importance of this morphological classification has been downsized in recent years since 
this distinction does not take into account important prognostic factors such as nuclear grading, 
necrosis, and architecture [1, 2]. However, a distinction between comedogenic and noncomedo-
genic DCIS remains very significant, because of the poorer prognosis of the comedogenic type, 
which is at higher risk of evolution toward invasive carcinoma and of local recurrence [3].
Several classifications were subsequently proposed [1], taking into consideration nuclear 
grading, presence of necrosis, histological architecture and pattern, lesion size, number of 
involved ducts, cell polarization, and positivity for some receptors. The most used classifica-
tion systems are those endowed with prognostic power.
2.1. Natural history
Several recent studies have shown that invasive breast cancer results from a progression of 
in situ cancer that proliferates and increases to overcome the basal membrane of the ductal 
epithelium, thus becoming infiltrating. However, the probability that all invasive carcinomas 
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originate from in situ forms is difficult to demonstrate, despite the many studies that have 
tried different approaches to achieve this. In particular, some studies focused on women with 
untreated DCIS, and some others used animals, as well as genomic studies of expression of 
cellular markers.
DCIS greatly differs from benign proliferative breast lesions for its biological and clinical fea-
tures. Alterations in the normal number of chromosomes occur in the evolution of breast 
lesions from benign hyperplasia to preinvasive malignant forms [4]. Heterozygosis lost occurs 
in more than 70% of high-grade DCIS, in 35–40% of atypical ductal hyperplasia, and in 0% of 
normal mammary tissue samples [5–7]. The p53 oncosuppressor gene is mutated in 25% of 
DCIS and only rarely in benign breast lesions [8]. Genomic analyses identified some genetic 
alterations related to the nuclear grading of DCIS [9]: loss of genetic material in the chro-
mosome 16q resulted associated with well or moderately differentiated DCIS, while DNA 
amplifications were related to a poorer differentiation. Thereafter, the genetic characteristics 
of DCIS were also compared with those of the adjacent invasive cell carcinomas, showing 
almost identical patterns.
Several other studies reported genetic similarities between invasive carcinoma and DCIS, 
especially high-grade DCIS, supporting the hypothesis that invasive carcinomas derive from 
the progression of preexisting DCIS [4, 10, 11]. The first step might be the abnormal response 
to growth factors, for example, mediated by estrogen receptors, which let the benign cells lose 
their ability to respond to normal apoptosis signals. Then, there would be the loss of function 
of some oncosuppressor genes as p53, the acquisition of some genetic instability with the 
loss of heterozygosity, and the onset of abnormal oncogenes such as HER2/neu. Finally, also 
changes in the surrounding stroma and neoangiogenesis occur, so that the preinvasive lesion 
becomes capable of invading the surrounding tissues for an imbalance between the gain of 
function by malignant cells and loss of function by the surrounding normal cells.
Many of the typical molecular characteristics of invasive lesions are already present in DCIS, 
such as genetic mutations, oncogenic expression, and loss of normal cell cycle regulation abil-
ity. The expression of molecular markers seems to have many points in common between in 
situ and invasive ductal carcinoma, supporting again the evolution of invasive carcinoma 
from DCIS. In the following section, these markers are discussed.
2.2. Biomolecular markers
The estrogen receptor is expressed in about 60% of DCIS [1] especially in those that exhibit 
less aggressive histological features such as low grading of differentiation and necrosis. The 
progesterone receptor expression seems to be consensual to that of the estrogen receptor.
HER2/neu is a member of the epidermal growth factor receptor (EGFR) family and is rou-
tinely studied in invasive carcinomas. It seems to be expressed by more than 40% of DCIS, 
especially by high-grade or comedogenic ones [12], so it would appear to be expressed in 
these lesions with a much higher frequency than that of invasive forms.
The expression of markers differs according to the nuclear grading of DCIS. In fact, consid-
ering only low-grade DCIS, some studies showed that in over 90% of cases it expresses the 
estrogen receptor, while in less than 20% of cases, it overexpresses HER2/neu or presents p53 
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mutations. In contrast, HER2/neu overexpression and p53 mutations are found in two thirds 
of high-grade DCIS, which expresses the estrogen receptor in only the 25% of cases.
2.3. Multifocal and multicentric disease
For its ability to spread within the ductal system, DCIS frequently presents with multiple out-
breaks within the same quadrant (multifocality) or in different quadrants (multicentricity). 
Multifocality occurs in two thirds of patients with low- or intermediate-grade DCIS, charac-
terized by a discontinuous growth. On the other hand, high-grade lesions tend to be continu-
ous, with neoplastic cell outbreaks usually not farer than 5 mm [4, 13, 14]. Other reports, albeit 
with lower incidence, show a higher frequency of multifocality and multicentricity in DCIS, 
and many authors highlighted how mammography is less sensitive than magnetic resonance 
imaging in such cases and underestimates the extent of the disease [4, 15].
In a very old study, Lagios and colleagues found that the incidence of multicentricity increases 
with the lesion size [16]. In addition, DCIS can spread through the ducts within the ductal sys-
tem to reach the nipple, without ever overcoming the basal membrane. This mode of growth 
characterizes Paget’s disease of the nipple, a rare manifestation of breast cancer that occurs 
with crusty and pruriginous nipple erythema.
3. Diagnosis and imaging
In the past, DCIS was clinically identified by objective examination by the presence of nipple 
discharge, Paget’s disease, or a palpable mass. Today, clinical finding is rare, and DCIS is 
mostly identified by mammography or magnetic resonance imaging.
3.1. Mammography
The sensitivity of mammography in detecting DCIS varies in the literature between 87 and 
95% [17–19]. In a comparative study of mammographic and anatomopathological findings, 
the number of high-grade lesions not detected in mammography was significantly low [18]. 
Microcalcifications are the expression of cellular debris and calcified secretions within the 
intraductal lumen; can be extremely variable in size, shape, and appearance; and account for 
about 60–75% of all mammographic abnormalities in case of DCIS [20–25].
The diagnostic approach to breast microcalcifications is the analysis of morphology, distribu-
tion, and eventual modifications over time. According to the terminology of BI-RADS, the 
morphology can be classified as “pleomorphic,” “linear,” “branched linear,” “amorphous,” 
or “indistinct.” The distribution of calcifications can be widespread or scattered throughout 
the breast, regional or distributed within a large volume of breast tissue (>2 cc), clustered if 
there are at least five calcifications in a small breast volume, segmental in the case where cal-
cific deposits lie in ducts or branches of a lobe or breast segment.
Considering the changes in microcalcifications over time, in the presence of doubtful but 
probably benign mammographic findings, the absence of modifications after a certain period 
of time is reassuring. On the other hand, as underlined in a retrospective study, in the case 
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of suspicious microcalcifications, the morphological aspect stability is not enough to exclude 
malignancy [26]. In this study, 25% of patients with malignancy finding at biopsy had micro-
calcifications with a stable appearance for 8–63 months. It is thus evident that morphology 
and distribution of microcalcifications are much more relevant in the decision-making pro-
cess of clinicians.
Several studies attempted to correlate the appearance of microcalcifications and other DCIS 
mammographic findings with the biology of these lesions [13, 20, 21, 26–34]. The layout of cal-
cifications reflects the localization of DCIS in the ductal system. Calcifications in a subareolar 
major duct may appear as a bundle of calcifications oriented toward the nipple. Calcifications 
in smaller ducts may have a branched appearance that reflects the extralobular endpoints, 
where most of the carcinomas originate. A branched radial pattern of calcifications means that 
intralobular endpoints are involved [21].
In several studies, most DCIS presented with granular microcalcifications [20, 27–31], but a 
radio-pathological correlation study showed that the histological type of DCIS cannot be accu-
rately determined on the basis of the morphological aspect of microcalcifications found in mam-
mography [31]. However, in this study, almost 80% of linear microcalcifications were associated 
with the comedogenic subtype, while granular microcalcifications were associated with non-
comedogenic DCIS subtypes in more than half cases [31]. Fine pleomorphic or linear-branching 
calcifications were significantly associated with high-grade DCIS and necrosis [25, 31], whereas 
round calcifications were significantly associated with low-grade DCIS [25]. Similarly, other 
mammographic studies showed that linear calcifications are most frequently expression of 
high-grade DCIS, while fine granular ones are more typical of well-differentiated DCIS [32–35].
Although microcalcifications are the most frequent mammographic finding in the diagnosis 
of DCIS, this may assume less commonly other radiological aspects. Various studies in the 
literature report more than 10% of DCIS presenting with solid mass aspect, usually with well-
defined margins [20, 21, 25]. This percentage rises if narrowing the survey to low-grade DCIS 
[17]. A mass-like aspect of DCIS may be the direct manifestation of a soft tissue mass or may 
be the result of periductal fibrosis, causing in this latter case an irregular or a bulging aspect 
of the mass [36].
Further mammographic manifestations include architectural distortion and focal asymme-
tries. Architectural distortion may also be determined by the sclerosis of the interstitial tissue 
surrounding the DCIS [21] or the tumor invasion of Cooper’s ligament [37]. Many low-grade 
DCIS appear to be mammographic masses or asymmetries [25] and, as a result, appear more 
frequently to be noncalcific lesions [34, 36]. Finally, Tabar et al. reported that the survival of 
women with masses or linear and linear-branching calcifications is considerably worse than 
women with other types of microcalcifications [38].
3.2. Magnetic resonance imaging
The use of magnetic resonance imaging (MRI) in the diagnosis of DCIS remains still an argu-
ment of great debate. The interest in using this tool for DCIS has grown following the brilliant 
results of its use in the invasive carcinoma. Initially, due to the different appearance of the 
two pathologies, this instrument was not considered adequate alone for the study of in situ 
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lesions. A fundamental factor which led MRI to become an important tool in the preopera-
tive diagnosis and evaluation of DCIS was the transition from high time resolution to high 
spatial resolution [39]. Another important factor is that MRI was used to study patients who 
had already been diagnosed with cancer by mammography, and only when MRI began to be 
used as a tool for screening on high-risk patients allowed more data to be compared about the 
accuracy of the two different diagnostic tools.
Several studies have been conducted to find out the multiple manifestations of DCIS by MRI 
and to correlate these with the biological characteristics of the disease. The superiority of MRI 
in the diagnosis of DCIS has been demonstrated in numerous studies with sensitivity rang-
ing from 86 to 92% [15, 40–43]. MRI sensitivity is higher for high-grade lesions, regardless 
of whether or not there is necrosis, which instead affects the sensitivity of mammography in 
identifying high-grade DCIS [41, 42, 44, 45]. The pattern of breast lesion enhancement corre-
lates with the biological profile of DCIS [46], because the diagnosis is based on tissue enhance-
ment after administration of a contrast medium and to the hyperdensity of neoplastic lesions 
due to vascular permeability [47].
Angiogenesis in DCIS may be partly due to the destruction of the cellular myoepithelial cell 
surrounding the ducts [48]. Myoepithelial cells tend to be more preserved in low-grade DCIS 
while being lost or significantly absent in high-grade DCIS or with comedic necrosis. Recent 
studies also show that focal damage to the myoepithelial layer could trigger tumor invasion. 
The tumor cells adjacent to the point of damage tend to be more frequently associated with 
genetic and phenotypic alterations, such as loss of estrogen receptors, reduced expression of 
oncosuppressors, and increased expression of genes related to the cell cycle, angiogenesis, 
and invasive capacity [49].
The terminology of BI-RADS includes three types of responses to breast MRI: “mass-like 
enhancement” defined as a three-dimensional injury occupying a generally rounded area of 
oval or irregular shape, “focal enhancement” defined as a small enhancement spot <5 mm 
that does not allow a further morphological description, and “non-mass-like enhancement” 
described as enhancement of an area without forming a mass. This last manifestation is most 
common in DCIS, present in 60–80% of cases [15, 24, 39, 41], while invasive or mixed ductal 
lesions appear in over 75% of cases as “mass-like enhancement” [41].
Non-mass-like enhancement lesions are distinguished on the basis of the distribution pattern 
as segmental, linear, ductal, focal, regional, multiregional, and diffuse. Segmental means a 
triangular enhancement area with the apex toward the nipple suggesting the distribution of 
a duct and its branches. Linear is defined as an enhancement area that may not correspond to 
a duct, while ductal indicates a linear enhancement zone with ramifications like a duct. The 
regional pattern has a large volume of enhancement that cannot be assimilated to a duct, and 
the focal enhancement is confined to a smaller area than 25% of a quadrant. The segmental 
distribution is the most common non-mass-like DCIS presentation [15, 24, 41].
On the basis of the internal enhancement pattern, non-mass-like enhancement lesions are 
distinguished also as clumped, heterogeneous, and homogeneous. The internal enhancement 
pattern can be clumped if it takes a cobbled appearance with occasional confluence areas. 
It may be homogeneous or otherwise heterogeneous when it is or not uniform. The most 
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common internal enhancement pattern is the clumped one (51.5%), followed by the heteroge-
neous (21%) and homogeneous ones (15%) [41].
Evaluation of kinetics in DCIS is less significant compared to invasive lesions, and in fact the 
extent of perfusion increases with the progression of lesions from benign to in situ and even 
more invasive lesions [47]. Based on the BI-RADS classification, the kinetic aspect of DCIS has 
been standardized, and two phases of the enhancement can be recognized: an initial phase, 
within the first 2 minutes after administration of the contrast medium, and a delayed phase 
after 2 minutes. The initial phase can be rapid, intermediate, or slow; the delayed phase can be 
classified as persistent (the signal continues to increase), plateau (the signal density does not 
change after the initial increase), or washout (the signal decreases after the initial climb). DCIS 
is usually characterized by the fast initial phase and a washout in the delayed phase [24, 50]. 
Moreover, there is no statistically significant difference in the kinetic characteristics between 
DCIS of different grading [24, 51].
Despite the superiority of MRI in terms of sensitivity, its role in the management of in situ 
disease remains still controversial. According to recent studies, the routine use of MRI in 
DCIS does not change the clinical management in 99% of patients and lead to more unneces-
sary reexamination and longer time interval before surgery [52]. In a recent meta-analysis, the 
proportion of patients who changed the treatment based on MRI findings results about 15% 
[53]. Available evidence suggests that the percentage of patients with noninvasive cancer who 
may benefit from a preoperative MRI assessment is not very high and should be weighed with 
the economic availability and the delay in definitive treatment resulting from the increase in 
preoperative investigations.
Patients undergoing MRI do not show a significant reduction in the re-intervention rate 
for positive margins after conservative surgery [53]. Several studies also show that the 
routine use of preoperative MRI is associated with a greater incidence of mastectomy 
for invasive carcinoma and the trend seems to be the same for DCIS [43, 53–56]. On the 
contrary, conservative surgery rates are higher among women who do not undergo pre-
operative MRI [53], and this probably reflects the MRI ability to detect multifocal and 
multicentric disease and results in a greater number of women who are not candidates 
for conservative surgery.
The identification of a subgroup of patients with DCIS that could benefit from preoperative 
MRI needs further studies on DCIS biology, in particular on its potential to progress and 
recur. In fact, as outlined in the literature, only 30–50% of cases of DCIS evolve to invasive dis-
ease if untreated [57, 58], and consequently many patients who undergo mastectomy for DCIS 
would receive an overtreatment; whether preoperative MRI results an advantage in terms of 
local control of disease and survival in patients with DCIS is still unclear.
However, many agree that there is definitely an improvement of surgical outcomes [52–54, 
59], and a study on DCIS and early invasive breast cancer does not reveal, after 4.6 years of 
median follow-up, significant differences in terms of recurrence, metastasis occurrence, mor-
tality, or contralateral lesions rate between patients undergoing or not preoperative MRI [60]. 
The use of MRI in addition to mammography could help in defining the exact extension of 
DCIS, although MRI often overestimates the size of the primitive tumor [59].
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3.3. Screening
Mammography is considered to be the most effective screening test for the detection of early 
breast cancer. In Italy, biennial mammography is recommended in women aged between 50 
and 69 [61, 62]. In women aged between 40 and 49, it should be performed only based on the 
familiar history, individual risk, and breast density, possibly accompanied by an ultrasound 
examination. In women aged over 70, there is no evidence of the effectiveness of mammo-
graphic screening, but the possibility of extending it to 75 years is considered. The relative 
reduction in mortality for breast cancer is 14% in women aged between 50 and 59 and 32% 
in the 60–69 range, reflecting the direct correlation of mammography sensitivity with age, 
related to the reduction in breast density [63].
MRI is not recommended as a screening survey in the general population [64] due to its 
low specificity and hence its higher number of false positives. The use of MRI as a screen-
ing method, in addition to mammography and clinical examination, is justified in high- and 
moderate-risk women, who include women with BRCA1 or BRCA2 mutations; previous 
chest wall radiotherapy between 10 and 30 years of age; Li-Fraumeni, Cowden, or Bannayan-
Riley-Ruvalcaba syndrome; personal history of DCIS; atypical ductal hyperplasia; and lobu-
lar intraepithelial neoplasia.
Tomosynthesis, which combines conventional, two-dimensional images with three-dimen-
sional, multilayer images, appears to be particularly effective in case of dense breasts, where 
the volumetric overlap of traditional mammography images prevents some lesions from 
being identified. In a study of 9672 women, the combination of mammography and tomosyn-
thesis increased not only the cancer detection rate but also the number of false positives [65].
The incidence of screen-detected DCIS varies between 15 and 30% [66–70]. It is greater in 
women aged between 40 and 49 (28.2%) than in older women (16–20.5%). The age-adjusted 
incidence rate increased from 2.4 to 27.7 per 100,000 women between 1981 and 2001 [36]. In line 
with these data, some studies reported an estimated annual DCIS incidence of 32.5 per 100,000 
women [71]. The overall screen-detected DCIS rate results 0.78 per 1000 mammograms, indi-
cating that one DCIS is approximately identified every 1300 screening mammograms [66].
The mammographic screening resulted in a mortality reduction of about 20–30% [72–74], but 
screening value remains uncertain in the case of DCIS. Some authors argue that it prevents 
the incidence of a large number of invasive tumors and contributes substantially to survival 
improvement. Others claim that this type of injury does not always progress to invasive can-
cer and in those cases it would not lead to death, and indeed, its response to screening would 
be a source of overdiagnosis, resulting in more harm than good [75]. The epidemiological 
definition of overdiagnosis is the difference between observed and expected incidences [70].
A study estimated that, of the 141 screened deaths, 17 were determined by the progression 
of DCIS to invasive carcinoma and therefore concluded that the detection of DCIS at screen-
ing prevented 12% of the overall avoided deaths with screening [75]. Another interesting 
evidence is that the majority of screen-detected DCIS are of high-grade and have a more pro-
nounced tendency to present necrosis, suggesting that screen-detected lesions have a higher 
risk of progression [76].
Cancer Management and Therapy178
The main objection to the screen detection of DCIS comes from the observation that misdi-
agnosed DCIS is much less likely than invasive tumors to become clinically evident [66]. In 
fact, it is evident that there are breast cancers that will never become lethal and that many 
women receive systemic therapies without knowing who will benefit from it, but the risk of 
overdiagnosis is lower than the benefits [70]. From a clinical point of view, the best and most 
prudent way to deal with DCIS is to consider it as a potential future invasive carcinoma [71].
4. Surgical treatment
The uncertainty about the natural history of DCIS and the impossibility to determine predic-
tive factors for which lesions will progress to invasive forms make the therapeutic choice 
extremely difficult. Initially, standard therapy was the simple mastectomy in 98–99% of 
patients [77]. Subsequently, with the introduction of always more conservative treatments 
for invasive carcinomas, the breast-conserving surgery (BCS) became progressively the most 
frequently used surgery for DCIS. There are, however, no randomized studies comparing 
outcomes after mastectomy and BCS [12, 64].
The currently recommended therapeutic options of the National Comprehensive Cancer 
Network (NCCN) include mastectomy and lumpectomy with or without radiotherapy and 
with the possible addition of tamoxifen in the case of hormone-positive DCIS. Randomized 
trials indicate that lumpectomy associated with radiotherapy results in the lowest recurrence 
rate but does not show any difference in overall and disease-free survival [78].
According to a recent article by Worni and colleagues, among 121,080 women with DCIS 
diagnosed from 1991 to 2010, most patients received radiotherapy (43%) after lumpectomy, 
followed by lumpectomy alone (26.5%), unilateral mastectomy (23.8%), bilateral mastectomy 
(4.5%), and ultimately no treatment (2.3%) [78]. In the 20 years of study, trends in the treat-
ment choice have changed, with a considerable increase in lumpectomy with radiotherapy 
(100% increase). Also, the significant increase in the number of bilateral mastectomies, a trend 
that seems to be driven more by the choice of bilateral prophylactic mastectomy than by the 
need to treat bilateral disease, is interesting.
4.1. Conservative breast surgery
Breast-conserving surgery (BCS) in the treatment of invasive breast cancer has gone affirm-
ing over the years, thanks to studies that demonstrated no significant difference in survival 
rates compared to mastectomy. However, this evidence has not yet been reached in the case 
of DCIS, and to date there are no randomized comparisons of mastectomy and BCS in women 
with DCIS. However, retrospective studies did not show any difference in the overall and 
disease-free survival between the two strategies [79, 80].
Several studies have been conducted in the attempt to determine the magnitude of the recur-
rence risk in patients with DCIS, in order to use this information to improve the therapeutic 
approach, but there are no definitive results on the effectiveness of BCS without radiotherapy, 
which, according to Worni et al., is still used today in about a quarter of cases [78].
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BCS consists in the excision of the lesion surrounded by about 1 centimeter of macroscopically 
health tissue. It may be a simple wide excision of breast parenchyma, also called lumpectomy, 
or a cylindrical excision of breast tissue including the overlying skin and the underlying mus-
cle fascia, also known as quadrantectomy [81]. In case of nonpalpable breast lesions, many 
different techniques can be used in order to intraoperatively guide the surgical resection, such 
as the preoperative placement of a wire hook or a radioactive tracer [82].
The specimen is then oriented with some stitched in order to facilitate the margin evaluation 
by the pathologist [83]. In particular, a negative margin greater than 2 mm represents nowa-
days the adequate margin for DCIS [84]. Moreover, in some cases also a cavity shaving may 
be performed, although there is no evidence that this procedure will significantly reduce re-
interventions for margin positivity.
4.2. Mastectomy
Mastectomy consists in the complete mammary gland excision together with the overlying 
skin and the nipple-areola complex, as well as the underlying muscle fascia. Nowadays, even 
more conservative techniques have been developed, so that it is possible to spare the skin with 
or without the nipple-areola complex by performing the so-called nipple-sparing mastectomy 
or skin-sparing mastectomy [85–91].
For what concerns these two last procedures, there are still controversies about the long-term 
oncological results, as, for example, the nipple includes the terminal portion of the breast 
ducts and may then represent a place at risk of recurrence. However, the esthetic results are 
undiscussed, and these kinds of techniques result in an essential improvement in the psycho-
physical wellness of women undergoing breast demolition.
Mastectomy is a healing process in 98–99% of patients with DCIS. The relapses after this 
intervention may be in situ but also invasive and can occur both as a local recurrence and a 
distant metastasis [77]. After mastectomy, the reported recurrence rate is less than 1.5% in 
most studies [92, 93]. The use of skin-sparing mastectomy does not correlate with a significant 
increase in local recurrences [93].
Recurrence after mastectomy for DCIS could be due to the lack of sampling or recognition of 
an invasive component or incomplete removal of the involved breast tissue. However, the fact 
that the majority of recurrences after mastectomy occur in the first 5 years suggests that most 
of these are due to the lack of recognition of an invasive carcinoma rather than the malignant 
transformation of the residual breast tissue [77].
Finally, mastectomy is an effective treatment for DCIS, but its use should be carefully evalu-
ated in the light of a pathology that does not present the risk of remote metastasis, typical of 
infiltrating forms, which will not necessarily become invasive.
5. Adjuvant treatments
Although DCIS is a local disease, the use of both local and systemic adjuvant therapies 
is widespread. In particular, adjuvant radiotherapy after BCS and the use of tamoxifen or 
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aromatase inhibitors are considered, while no evidence supports the use of adjuvant chemo-
therapy in the treatment of DCIS [64].
5.1. Radiation therapy
With the introduction of adjuvant radiotherapy after BCS for invasive breast carcinoma, the 
interest in radiotherapy application for DCIS has also greatly increased. A lot of studies in the 
literature evaluated the efficacy of this treatment in DCIS patients, and according to the current 
guidelines, radiotherapy after BCS results is strongly recommended in patients with DCIS [64].
Breast irradiation usually includes all the residual breast (whole breast irradiation), is classi-
cally performed within 6 months after surgery, and usually consists in 25 sessions, even if also 
shorter hypofractionated protocols are described. Anyway, radiation therapy may be also 
limited to the area surrounding the tumor (partial breast irradiation) and be performed intra-
operatively immediately after the tumor excision, as happens for the intraoperative radio-
therapy (IORT) [94].
A recent meta-analysis of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) on 
individual data from four randomized studies showed that adjuvant radiotherapy reduces 15.2% 
of the absolute risk of 10-year ipsilateral invasive relapse after surgery for DCIS, anyway without 
any significant effect on survival [95]. These data confirm the findings of previous international 
randomized trials that generally showed a reduction by about 50–60% in ipsilateral breast recur-
rences in patients who received radiotherapy after BCS compared to BCS alone [96–99].
Recurrences after BCS for DCIS are usually half invasive and half in situ. With the addition of 
radiotherapy to BCS, the annual invasive recurrence rate results about 0.5–1%. The possible 
benefits of this therapeutic choice on survival would be the reduction of invasive recurrences 
and the consequent reduction of mortality [77, 98].
According to recent reports, most patients are subjected to lumpectomy followed by radio-
therapy, and this therapeutic option raised from the 25% of treatments in 1991 to the 50% in 
2010 [78]. Patients who refuse radiotherapy after BCS should be properly informed of the 
potential for greater local recurrence risk, although a survival benefit may not yet be evi-
denced by studies due to the insufficient number of patients examined and to the very low 
mortality rate for this disease [71].
5.2. Hormonal therapy
Given the important role of the estrogenic pathway in the pathogenesis of breast carcinomas, 
many strategies have been developed which can control estrogen-sensible tissues. The first 
experimented drug was tamoxifen, a selective estrogen receptor modulator (SERM), which 
has the ability to act as an estrogenic agonist in certain tissues such as bone and endometrium, 
while it acts as a powerful estrogenic antagonist in others including the breast. For these prop-
erties it is widely used in the treatment of invasive breast cancer, where it has been shown to 
reduce the risk of relapse and death after surgical treatment [100].
The role of adjuvant therapy with tamoxifen for DCIS was analyzed in two major randomized 
trials. The NSABP B-24 study randomized 1804 women with DCIS between BCS followed by 
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radiotherapy and tamoxifen for 5 years versus BCS followed by radiotherapy and placebo for 
5 years [101]. This study demonstrated a significant reduction of events after 5 years in the 
tamoxifen group compared to the placebo one. In particular, a reduction was observed in the 
risk of invasive relapse in both the ipsilateral and the contralateral breasts. However, for what 
concerns noninvasive relapses, the addition of tamoxifen was not proven to be significant.
The benefit in women treated with tamoxifen was also significant after 163 months of follow-
up [95], and over 15 years of follow-up, adjuvant tamoxifen reduced the risk of recurrence 
of ipsilateral breast cancer by 31% [99]. A retrospective analysis, conducted on 41% of the 
original study population, evaluated the relationship between estrogen receptor expression 
and tamoxifen benefit. It has been shown that treatment with tamoxifen significantly reduced 
the risk of subsequent breast cancer at 10 and 14.5 years, while in patients without expression 
of estrogen receptors, no benefit was observed. Finally, there were no differences in survival 
between the two arms of the NSABP B-24 trial.
The randomized phase II trial UK/ANZ DCIS93 evaluated the role of radiotherapy and 
tamoxifen in the treatment of patients undergoing BCS for DCIS, enrolling 1701 patients [102]. 
It analyzed the following therapeutic approaches: surgery alone, surgery followed by radio-
therapy, surgery followed by tamoxifen for 5 years, and surgery followed by both radiother-
apy and tamoxifen for 5 years. As for the use of tamoxifen, at 12 years of median follow-up, 
the study showed a reduction of ipsilateral in situ relapses, while there seemed to be no effect 
on the invasive ipsilateral recurrence.
Considering these two trials as a whole, it emerges that adjuvant tamoxifen, associated with 
radiotherapy, reduces the risk of in situ ipsilateral recurrences in the case of DCIS which 
expresses hormonal receptor, independently by the patient’s age [48, 64]. Thereafter, the deci-
sion whether to propose tamoxifen as adjuvant treatment should be based on the evaluation 
of its side effects and potential benefits.
In postmenopausal women with invasive breast cancer, the aromatase inhibitors have been 
shown to be more effective than tamoxifen in reducing recurrences and preventing new con-
tralateral cancers after surgery [100]. The second International Breast Cancer Intervention 
Study (IBIS-II) had the aim of studying the role of aromatase inhibitors in both primary pre-
vention and adjuvant therapy in women with DCIS [102]. The NSABP B-35 study had simi-
lar objectives and compared tamoxifen with anastrozole for 5 years in 3000 postmenopausal 
women who underwent surgery and radiotherapy for DCIS, and, at a median follow-up of 
8.6 years of treatment, anastrozole significantly improved the disease-free survival [103].
5.3. Other medical therapies
HER-2/neu is overexpressed in a variable number of DCIS [100] and appears to be related to 
an increase in local recurrences [104]. A retrospective analysis of 10,853 women enrolled in 
the EORTC trial showed that, of the 31 local relapses occurring in patients with DCIS, 24 were 
associated with in situ lesions that overexpressed HER-2/neu. The real meaning of HER-2/
neu overexpression in DCIS is currently the object of the study, given its importance as a 
prognostic and predictive factor in the invasive cancer. The use of trastuzumab, a monoclonal 
antibody targeting HER-2/neu, is interesting given the relative frequency of its presence in 
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the DCIS and the lack of effective medical therapies for DCIS which does not express estrogen 
receptors. These considerations have led to the development of two studies on the role of 
trastuzumab in DCIS. The first study, conducted by Gonzalez et al. with not yet conclusive 
results, evaluated the benefit of neoadjuvant trastuzumab in DCIS of less than 1 cm. The sec-
ond one, conducted from the NSBP, has not yet been completed.
6. The microinvasive component
In agreement with the American Joint Committee on Cancer, microinvasive breast cancer 
is defined as a DCIS where the invasive component is microscopic and does not exceed the 
size of 1 mm [105]. In the current literature, microinvasive cancer prevalence accounts for 
about 10–20% of DCIS cases, and it does not represent more than 1% of all breast cancers 
[1, 106–110].
The natural history of these lesions is unclear; however, DCIS with microinvasion could be an 
intermediate stage in the invasive evolution. As a proof of this, the microinvasive carcinoma 
is often associated with DCIS, particularly large and with comedonecrosis [1, 64], and may 
be formed by small foci of tumor cells that, after crossing the basal membrane, infiltrate the 
surrounding stroma [64]. The age of presentation does not seem to be significantly different 
from that of invasive or in situ forms [106].
Almost all DCIS with microinvasion are identified by the presence of microcalcifications 
at mammography [111]. Occasionally, the microinvasive carcinoma appears as a palpable 
mass with serum or blood vessel secretions from the nipple or as Paget’s disease [112–114]. 
Microinvasive lesions tend to be larger in size and therefore more often palpable than purely 
in situ lesions. The detection of a microinvasion within a DCIS can be extremely difficult for 
the pathologist because of the many patterns with which the lesion can invade the stroma [77]. 
Usually, the microinvasion foci tend to be accompanied by a stromal response characterized 
by inflammatory cells scattered in one neoformed connective matrix [115]. Moreover, the use 
of immunohistochemical markers specific for the basal membrane or myoepithelial cells can 
help identify microinvasion in doubtful cases [115].
Concerning the therapeutic implications, data is not uniform. Surgical treatment can be both 
conservative and radical. According to recent reports, the use of mastectomy is significantly 
less frequent for this type of lesion than for invasive carcinomas, and the same happens for 
adjuvant therapies, generally reserved only for patients with triple-negative carcinomas, 
HER2-positive breast cancer, or with lymph node involvement [106]. The use of adjuvant 
radiotherapy is even higher in the group of microinvasive carcinoma than in that of invasive 
one, possibly due to the higher prevalence of conservative surgery.
According to the AIOM guidelines, mastectomy is indicated in these tumors in the presence of 
large intraductal component, particularly unfavorable histological characteristics (high-grade 
and comedonecrosis), or when it is not possible to obtain an adequate resection margin with 
a conservative resection [64]. BCS is also contraindicated after previous chest wall irradiation, 
during pregnancy, or in the case of multicentric lesions or diffused microcalcifications [110].
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Regarding the use of adjuvant systemic treatments, endocrine therapies may be administered 
in the case of hormone receptor expression, while chemotherapy is not indicated, except in 
patients with axillary lymph node metastases [64, 106]. There are currently no prospective 
randomized studies comparing BCS followed by radiotherapy with mastectomy in the subset 
of patients with microinvasive carcinoma [105].
Prior to the spread of the sentinel lymph node technique, due to its significant morbidity 
and poor clinical benefits, axillary dissection was not recommended in the management of 
noninvasive or microinvasive lesions [109]. With the introduction of the sentinel lymph node 
biopsy, burdened with much minor complications, axillary surgery has extended also to DCIS 
in the case of mastectomy, as the technique would not be reliable in the second time if needed 
[116, 117]. However, in the literature there is insufficient evidence of the efficacy of the senti-
nel lymph node biopsy for the microinvasive cancer, mainly because the studies are mostly 
retrospective and based on small sample sizes.
The detection of microinvasive foci at the definitive histological examination of specimen of 
women initially diagnosed with DCIS is quite frequent. In particular, the upstaging rate to 
invasive carcinoma varies in the literature about 10–20% of in situ or microinvasive lesions 
[118]. In the case of unexpected microinvasive carcinoma, the sentinel lymph node biopsy can 
be performed both in conjunction with the primary lesion excision and later on.
In the literature, the sentinel lymph node metastasis rates reported in the case of microinvasive 
carcinomas are about 6–10%, and about half of these are micrometastasis [77]. In a recent meta-
analysis, Gojon et al. studied the role of the lymph node biopsy in 968 patients with microinva-
sive carcinoma [116]. It emerged that the macrometastasis rate in the sentinel lymph nodes was 
3.2% (CI (95%): 2.1–4.6%) without significant differences between the data of the various con-
sidered studies. Patients with macrometastatic sentinel nodes would have a risk of almost 30% 
of having more non-sentinel lymph node metastases, but, due to the rarity of nodal macrome-
tastases, the global incidence of non-sentinel metastases in microinvasive carcinoma resulted 
less than 1%. Thereafter, given the low rates of nodal positivity, this meta-analysis does not 
justify the routine use of sentinel lymph node biopsy in patients with microinvasive carcinoma.
Several studies have tried to identify predictive factors for lymph node involvement but 
with contrasting results [116]. In addition, many studies have reported excellent prognosis 
in patients with microinvasive carcinoma, irrespective of the eventual asynchronous lymph 
node involvement [116]. Some authors reported a similar local or distant recurrence risk in 
patients with in situ or microinvasive carcinomas and positivity for sentinel lymph biopsy 
[119]. Then, despite the absence of clear scientific evidence, in the case of microinvasive can-
cer, the use of the sentinel lymph node biopsy is still recommended, especially given the low 
morbidity of this practice [77].
The survival of patients with microinvasive carcinoma seems to be a halfway between that 
of pure DCIS and that of early invasive carcinoma [77]. Some dated studies reported no 
recurrence after average follow-up of 57 and 47 months, respectively [112, 113]. Kinne et al. 
reported a disease-free survival of about 94% at a median follow-up of 11.5 years [120]. Solin 
et al. compared the outcomes of invasive carcinoma with those of DCIS and microinvasive 
carcinoma treated in the same period [114] and found that patients with microinvasive cancer 
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had a higher local recurrence rate than those with pure DCIS, as well as an intermediate sur-
vival rate between in situ and frankly invasive carcinomas. In contrast, Silverstein and Lagios 
did not detect differences between patients with microinvasive carcinoma and DCIS in terms 
of overall and disease-free survival [121].
In a review of Adamovich and Simmons, the median time of appearance of a local relapse 
resulted in 42 months, most of the local recurrences of microinvasive carcinoma were inva-
sive recurrences, and only the 7% were distant ones [110]. A study by Parikh et al. on 393 
women with breast cancer treated with BCS and radiotherapy suggested that microinvasion 
is not predictive of a significant worsening of local recurrence and distant metastasis-free 
survival, overall survival, and disease-free survival [122]. This study concluded that, despite 
the greater aggressiveness in treating patients with microinvasion, clinical and pathological 
characteristics and outcome did not differ for DCIS with and without microinvasion. Even 
more recent data emerging from Fang et al.’s work confirmed that disease-free survival of 
over 2 years in patients with microinvasive carcinoma was significantly worse than that of 
pure DCIS and similar to that of invasive carcinoma smaller than 5 mm [106].
In conclusion, clinical and pathological features and outcomes do not significantly differ 
between DCIS with and without microinvasion [106]. Overall survival do not differ signifi-
cantly in the two groups, which altogether have a good prognosis overall. The prevalence of 
lymph node metastases in the microinvasive carcinomas is low and does not associate with a 
prognosis worsening, as it does not lead to an increased risk of recurrence, either local or dis-
tant [119]. According with the ASCO guidelines published in 2016, a 6-month clinical follow-
up together with annual instrumental examinations should be recommended [123].
7. The role of sentinel lymph node biopsy
Complete axillary dissection was the only possible approach in surgery until the early 1990s of 
the last century. Nowadays, the sentinel lymph node biopsy represents the standard in most 
centers that deal with mammary surgery [64, 82, 124–127] and significantly reduced the com-
plications associated with axillary surgery [128] while providing high levels of accuracy in the 
staging [129–131]. The multicentric NSABP B-32 trial randomized 5611 women with clinically 
negative axillary nodes to the sentinel lymph node biopsy alone or followed by axillary dis-
section [131]. No significant differences in disease-free and overall survival and locoregional 
recurrences were observed between the two groups at a median follow-up of 96 months.
The concept of sentinel lymph node was born in the 1970s and completely developed 
20 years later, based on the principle that tumors are drained from a lymphatic channel 
through the first sentinel node of that region. In 1991 Giuliano and colleagues first applied 
the method of sentinel lymph node biopsy at the John Wayne Cancer Institute in the context 
of breast surgery. They reached 100% accuracy in predicting axillary nodal status in a few 
years [125, 132, 133], opening the way to the spread of the method.
In a recent work, analyzing data from the Surveillance, Epidemiology, and End Results 
(SEER) registers, Worni and colleagues reported that in 2010 the sentinel lymph node biopsy 
Breast and Axilla Treatment in Ductal Carcinoma In Situ
http://dx.doi.org/10.5772/intechopen.74340
185
was performed in over 70% of mastectomies for DCIS and in at least 20% of lumpectomies. 
The indications of the sentinel lymph node biopsy for DCIS are not always supported by sci-
entific evidence and are sometimes the result of a consensus of experts, leading to a significant 
variability among the various centers dealing with breast surgery.
8. Local recurrences
The local recurrence rate after surgery for DCIS, associated or not with subsequent radio-
therapy, ranges from 0 to 10% at 5 years and from 8 to 23% at 10 years [77]. A study on a large 
number of patients undergoing conservative surgical excision and radiotherapy, conducted 
by an international group, described a recurrence rate at 5, 10, and 15 years of, respectively, 
6, 11, and 16% [134]. The cumulative annual local recurrence rate found in this study was 
approximately 1% and was thus lower than that reported by the NSABP trial, which is 1.8%. 
This value is similar to that found for invasive carcinoma treated in the same way [77].
Many prognostic factors of local recurrence have been hypothesized in patients with DCIS 
treated with BCS, associated or not with complementary radiation therapy. In almost all stud-
ies, the margin involvement was correlated with a higher local recurrence rate. On the other 
hand, the local recurrence rate is lower after radical excision with negative margins. However, 
the adequate distance of the excision margin from the lesion is not precisely defined [77].
In some studies, negative margins of 0 mm (also defined “no ink on tumor”) were compared 
with negative margins up to 10 mm from the lesion, concluding that wider margins give more 
protection against recurrences [135]. In a meta-analysis conducted by Dunne et al., consider-
ing the effect of the state of margins after BCS and radiotherapy, the highest recurrence rate 
was observed among women with excision margins of less than 2 mm, whereas for margins 
greater than 2 mm, no further benefits were observed in comparison to margins of 5 mm or 
more [136]. Therefore, these data imply that for women receiving BCS and radiotherapy, 2 mm 
margins can be considered adequate to reduce as much as possible the risk of recurrences.
However, without the addition of radiotherapy, conservative surgery with margins lower 
than 10 mm results in a greater recurrence risk (of more than fivefold), while with the addition 
of radiation therapy, there seems to be no additional benefit for larger margins [137]. Anyway, 
no successful study has been performed to compare women with greater or lesser margins, 
which may conclude for a benefit of a certain margin distance [71].
Young patients show a consistently higher risk of local recurrence than older patients. The 
reasons for this difference are not clear, but a study found that younger patients tend to have 
smaller excision volumes, higher prevalence of high-grade tumors, and higher frequency of 
necrosis [138, 139]. On the other hand, another study did not confirm these differences in 
terms of pathological characteristics between the two groups of patients and identified in 
younger women a higher rate of HER2/neu overexpression [140].
Histological features have been evaluated in several studies with different results. From the 
EORTC87 trial, the local recurrence rate at 5.4 years of follow-up proportionally increased 
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together with the increase of high-grade tumor (8, 14, and 18%, respectively, for low-, inter-
mediate-, and high-grade lesions). This data is confirmed by the NSABP B-17.89 trial, which 
also revealed a difference between low-grade tumors with or without necrosis in terms of local 
recurrences. Between groups of patients with tumors of different grading, but both involving 
necrosis, recurrence rates did not seem to substantially differ. Moreover, necrosis has been 
identified as a risk factor for recurrence in many other studies, and comedonecrosis is strongly 
associated with worse outcome and increased risk of invasive recurrences [98, 140, 141].
The size of DCIS was evaluated in several studies but without definitive responses, also due 
to the difficulty and lack of uniformity in measuring this kind of lesions [77]. In general, larger 
tumors have been associated with higher rates of recurrence, both in situ and invasive [93, 142].
A further step forward in the prediction of relapse could be the evaluation of the biomolecu-
lar profile, through the study of molecular marker expression. In fact, the positivity for the 
estrogen receptor has been reported to be associated with a reduction in the risk of recurrence, 
while the HER2/neu overexpression seems to be associated with an increased incidence of 
local recurrences [143]. The frequency of expression of HER2/neu in DCIS in some reports 
exceeds the 40%.
In an attempt to summarize all these predictive factors of recurrence, Silverstein and col-
leagues developed the Van Nuys Prognostic Index that considers four important variables, 
each of which is assigned a score from 1 to 3, generating a total score ranging from a score of 
4 (predicting the best prognosis) to 12 (predicting the worst prognosis) [144, 145]. The ana-
lyzed variables are the size of the lesion, the margin amplitude, the pathological classification 
including the nuclear grading and the eventual presence of comedonecrosis, and the patient 
age. The prognostic utility of this score was confirmed by NSABP B-17 trial, and, since half of 
the local recurrences after BCS were invasive carcinomas, it is very important to evaluate the 
outcome of the rescue treatment in these patients [146].
Solin et al. studied 41 cases of local relapse in 422 women with DCIS treated with BCS followed 
by radiotherapy [134]. The median time to local relapse was 4.8 years. In 22 of these 41 patients, 
the relapse was invasive. Among these lasts, after 4 years from the local recurrence, in 19% of 
cases, a distant metastasis occurred, and 13% died as a consequence. On the other hand, none 
of the patients with a noninvasive local relapse experienced metastasis or died due to cancer.
Another study presented similar data, with a 15% of distance metastasis rate after 12 years 
from invasive local relapse and a 12% mortality rate in this group of women [92]. These stud-
ies show how important it is, in the field of BCS, to minimize the risk of invasive local recur-
rence and consequently the risk of distant metastasis, which are associated with a significantly 
higher risk of death for cancer-related causes.
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